A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc.
Pfizer
University of California, Irvine
Pfizer
Incyte Corporation
Novartis
Abramson Cancer Center at Penn Medicine
Fate Therapeutics
M.D. Anderson Cancer Center
Enliven Therapeutics
M.D. Anderson Cancer Center
SillaJen, Inc.
Nurix Therapeutics, Inc.
First Affiliated Hospital of Zhejiang University
Leap Therapeutics, Inc.
Toray Industries, Inc
Washington University School of Medicine
Shanghai Junshi Bioscience Co., Ltd.
DEKA Biosciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adlai Nortye Biopharma Co., Ltd.
Jazz Pharmaceuticals
Eli Lilly and Company
National University Hospital, Singapore
AbbVie
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sumitomo Pharma America, Inc.
Canadian Cancer Trials Group
Fox Chase Cancer Center
M.D. Anderson Cancer Center
Athenex, Inc.
Fox Chase Cancer Center
Novartis
Gilead Sciences
M.D. Anderson Cancer Center
AnewPharma
Jiangsu HengRui Medicine Co., Ltd.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
AbbVie
Maastricht Radiation Oncology
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey